ORYZON to provide corporate progress updates at several events in January-February

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an update on corporate progress at several international events in January-February.

Oryzon has been invited to participate at the 8th Sachs Annual Neuroscience Innovation Forum, which will be held on January 12 at the Marines’ Memorial Club in San Francisco (USA). The company will provide a corporate update on its CNS program at 10:55 am PST (Track A - Room Rosenberg). Oryzon will also take part in a panel entitled “Revolutionizing Neuropsychiatric Treatments: Novel Approaches” at 1:15 pm PST (Commandants Room). Click on link for more info about the 8th Sachs Annual Neuroscience Innovation Forum.

Oryzon has been invited to participate at the 14th Annual LifeSci Advisors Corporate Access Event, which will be held at the Beacon Grand Hotel in San Francisco (USA) on January 13-15, where the company will maintain meetings with investors and pharma companies. Click on link for more info about 14th Annual LifeSci Advisors Corporate Access Event.

Oryzon will attend the Invest Securities BioMed Forum 2025, which will be held at the Salons Hoche in Paris (France) on February 4.

Oryzon will participate at the Midcap Events 2025, which will take place at the Steigenberger Icon Hotel in Frankfurt (Germany) on February 13, where Oryzon will hold one-on-one meetings with investors. Click on link for more info about the Midcap Events Frankfurt 2025.

Oryzon will also attend Bio-Neuroscience 2025, which will be held at the Hotel Jakarta in Amsterdam (Netherlands) on February 25-27. Click on link for more info about Bio-Neuroscience 2025.